Eidos Therapeutics confirms receipt of non-binding proposal from BridgeBio Pharma to acquire shares

This article was originally published here

BridgeBio currently owns, through its wholly-owned subsidiary, BridgeBio Pharma LLC, approximately 66.6% of the outstanding shares of the Company’s common stock. According to the terms of the Proposal,

The post Eidos Therapeutics confirms receipt of non-binding proposal from BridgeBio Pharma to acquire shares appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply